A Cochrane Systematic Review that set out to assess the effectiveness and tolerability of subdermal implantable contraceptives compared to other reversible methods of contraception found that they ...

The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...

Clinical data support a 5-year duration for the Nexplanon implant, with no reported pregnancies during the extended 2-year study period. The Food and Drug Administration (FDA) has extended the ...